Cargando…

Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea

BACKGROUND: In South Korea, about 20 types of antiretroviral drugs are used in the treatment of patients with human immunodeficiency virus/acquired immune deficiency syndrome. Since 2010, raltegravir, etravirine, and darunavir have been spotlighted as new drugs for highly active antiretroviral thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwon, Oh-Kyung, Kim, Sung Soon, Rhee, Jee Eun, Kee, Mee-Kyung, Park, Mina, Oh, Hye-Ri, Choi, Ju-yeon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404133/ https://www.ncbi.nlm.nih.gov/pubmed/25879840 http://dx.doi.org/10.1186/s12985-015-0283-7

Ejemplares similares

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection
por: Rosso, R, et al.
Publicado: (2009)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
por: Tyrer, M, et al.
Publicado: (2010)

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
por: Kakuda, Thomas, et al.
Publicado: (2012)

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study
por: Portilla, Joaquín, et al.
Publicado: (2014)

Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1
por: Viani, Rolando M
Publicado: (2010)

Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism
por: Belkhir, Leïla, et al.
Publicado: (2016)

Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial)
por: Charpentier, Charlotte, et al.
Publicado: (2013)

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial
por: Arathoon, Eduardo, et al.
Publicado: (2017)

The role of etravirine in the management of treatment-experienced pediatric patients with HIV
por: Osterholzer, Danielle
Publicado: (2013)

Profile of darunavir in the management of treatment-experienced HIV patients
por: Wolfe, Cameron, et al.
Publicado: (2009)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand
por: Lyons, Alex, et al.
Publicado: (2022)

The Recency Period for Estimation of Human Immunodeficiency Virus Incidence by the AxSYM Avidity Assay and BED-Capture Enzyme Immunoassay in the Republic of Korea
por: Yu, Hye-Kyung, et al.
Publicado: (2014)

Profile of etravirine for the treatment of HIV infection
por: Tseng, Alice, et al.
Publicado: (2010)

Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age
por: MacBrayne, Christine E., et al.
Publicado: (2021)

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
por: Neely, Michael, et al.
Publicado: (2009)

2482. Clinical Outcomes of Once-Daily Darunavir in Treatment-Experienced Patients with Darunavir Resistance Associated Mutations Through 48 Weeks of Treatment
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2019)

Modification of AxSYM Human Immunodeficiency Virus Assay to Identify Recent Human Immunodeficiency Virus Infections in Korean Human Immunodeficiency Virus-Positive Individuals
por: Wang, Jin-Sook, et al.
Publicado: (2015)

The burden and characteristics of tuberculosis/human immunodeficiency virus (TB/HIV) in South Korea: a study from a population database and a survey
por: Lee, Chang-Hoon, et al.
Publicado: (2010)

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
por: Mulligan, Nikki, et al.
Publicado: (2016)

Effectiveness, Safety, and Tolerability of a Switch to Dual Therapy with Dolutegravir Plus Cobicistat-Boosted Darunavir in Treatment-Experienced Patients with Human Immunodeficiency Virus
por: Lee, Sang-Ah, et al.
Publicado: (2018)

Forecasting the Number of Human Immunodeficiency Virus Infections in the Korean Population Using the Autoregressive Integrated Moving Average Model
por: Yu, Hye-Kyung, et al.
Publicado: (2013)

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2014)

Immune Status and Epidemiological Characteristics of Human Immunodeficiency Virus Seroconverters in Korea, 1999–2009
por: Wang, Jin-Sook, et al.
Publicado: (2012)

Hospital-based HIV/HSV-2 seroprevalence among male patients with anal disease in Korea: cross sectional study
por: Wang, Jin-Sook, et al.
Publicado: (2014)

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
por: Orrell, Catherine, et al.
Publicado: (2015)

Prevalence of Primary Immunodeficiency in Korea
por: Rhim, Jung Woo, et al.
Publicado: (2012)

Epidemiological and Immunological Characteristics at the Time of HIV Diagnosis for HIV/AIDS Cohort Registrants Representative of HIV-Infected Populations in Korea
por: Lee, Jin-Hee, et al.
Publicado: (2012)

Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS
por: Putcharoen, Opass, et al.
Publicado: (2015)

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
por: Geretti, Anna Maria, et al.
Publicado: (2015)

Decreased Phenotypic Susceptibility to Etravirine in Patients with Predicted Genotypic Sensitivity
por: Agneskog, Eva, et al.
Publicado: (2014)

Experimental data of co-crystals of Etravirine and L-tartaric acid
por: Rekdal, Mikal, et al.
Publicado: (2017)

Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients: Observational Data from the Randomized POTENT Trial
por: Elgadi, Mabrouk M., et al.
Publicado: (2012)

Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients
por: Mata-Marín, José Antonio, et al.
Publicado: (2015)

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2016)

Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
por: Solana-Altabella, Antonio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rvinckl02dhmvqipq2bsjgsba6